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Abstract
Background: Blood neurofilament light (Nfl) and total-tau (t-tau) have been described to be increased in several
neurological conditions, including prion diseases and other neurodegenerative dementias. Here, we aim to
determine the accuracy of plasma Nfl and t-tau in the differential diagnosis of neurodegenerative dementias and
their potential value as prognostic markers of disease severity.
Methods: Plasma Nfl and t-tau were measured in healthy controls (HC, n = 70), non-neurodegenerative neurological
disease with (NND-Dem, n = 17) and without dementia syndrome (NND, n = 26), Alzheimer’s disease (AD, n = 44),
Creutzfeldt-Jakob disease (CJD, n = 83), dementia with Lewy bodies/Parkinson’s disease with dementia (DLB/PDD, n =
35), frontotemporal dementia (FTD, n = 12), and vascular dementia (VaD, n = 22). Biomarker diagnostic accuracies and
cutoff points for the diagnosis of CJD were calculated, and associations between Nfl and t-tau concentrations with
other fluid biomarkers, demographic, genetic, and clinical data in CJD cases were assessed. Additionally, the value of
Nfl and t-tau predicting disease survival in CJD was evaluated.
Results: Among diagnostic groups, highest plasma Nfl and t-tau concentrations were detected in CJD (fold changes of
38 and 18, respectively, compared to HC). Elevated t-tau was able to differentiate CJD from all other groups, whereas
elevated Nfl concentrations were also detected in NND-Dem, AD, DLB/PDD, FTD, and VaD compared to HC. Both
biomarkers discriminated CJD from non-CJD dementias with an AUC of 0.93. In CJD, plasma t-tau, but not Nfl, was
associated with PRNP codon 129 genotype and CJD subtype. Positive correlations were observed between plasma Nfl
and t-tau concentrations, as well as between plasma and CSF concentrations of both biomarkers (p < 0.001). Nfl was
increased in rapidly progressive AD (rpAD) compared to slow progressive AD (spAD) and associated to Mini-Mental
State Examination results. However, Nfl displayed higher accuracy than t-tau discriminating CJD from rpAD and spAD.
Finally, plasma t-tau, but not plasma Nfl, was significantly associated with disease duration, offering a moderate survival
prediction capacity.
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Conclusions: Plasma Nfl and t-tau are useful complementary biomarkers for the differential diagnosis of CJD.
Additionally, plasma t-tau emerges as a potential prognostic marker of disease duration.
Keywords: Dementia, Creutzfeldt-Jakob disease, Biomarkers, Plasma, Neurofilament light, Tau, Diagnosis, Disease
progression
Background
Neurodegenerative dementias are a group of clinically het-
erogeneous diseases characterized by gradual progression
of cognitive dysfunction, psychiatric and behavioral symp-
toms, and movement deficits. They can be associated ei-
ther with the aggregation and accumulation of misfolded
proteins (i.e., Alzheimer’s disease (AD), fronto-temporal
dementia (FTD), dementia with Lewy bodies (DLB),
Parkinson’s disease dementia (PDD), and Creutzfeldt-
Jakob disease (CJD)) or with brain damage due to im-
paired blood flow, leading to vascular dementia (VaD).
The presence of overlapping symptomatology in neurode-
generative dementias is frequent, thus differential diagnosis,
currently based on clinical evaluation and biological and
topological markers, may be challenging [1–3]. Cerebrospinal
fluid (CSF)-based tests for total-tau (t-tau), phospho-tau (p-
tau) and amyloid β (Aβ42) are included in the diagnostic cri-
teria of AD [4], while 14-3-3 protein and PrPSc detection by
the real-time quacking induced conversion (RT-QuIC) are
included in the diagnostic criteria of CJD [5, 6]. Other CSF
biomarkers such as neurofilament light (Nfl) are increased in
the CSF of all neurodegenerative dementias studied, as well
as in motor neuron diseases, being considered as a general
marker of neurodegeneration. Its low specificity undermines
its potential use in the differential diagnostic context, but fa-
vors its use to identify and grade, or exclude, neurodegenera-
tion. In addition, the observation that Nfl is associated to
survival and disease severity in many neurodegenerative con-
ditions suggests a potential role as dynamic and prognostic
marker [7–9].
Blood-based biomarkers offer important advantages
over CSF-based biomarkers. In contrast to lumbar punc-
ture, blood collection is time- and cost-effective and can
be easily obtained in primary care. Thus, development of
blood-based assays may lead to the implementation of
non-invasive front-line tests for early diagnosis, screen-
ing of populations, and follow-up analysis of patients
(disease monitoring). Despite the potential advantages of
blood biomarkers, the low concentrations of brain-
derived biomarkers in blood impeded their study and
validation as robust biomarkers until the recent develop-
ment of antibody-based ultrasensitive technologies [10].
In this regard, alterations of brain biomarkers in blood
have been recently reported in several neurodegenerative
dementias. Nfl and t-tau are two of the most promising
ones to be translated into clinical grounds regarding
their diagnostic and prognostic value, especially in CJD,
where both proteins are highly increased compared with
controls and other neurodegenerative diseases [11–16].
Since Nfl and t-tau are associated with neuronal damage,
a common hallmark in neurodegenerative dementias, it
is crucial to determine their specificity and accuracy in
the differential diagnostic context.
The main objective of this study was to validate previous
observations on the diagnostic accuracy of plasma Nfl and
t-tau in CJD with additional consideration of relevant
non-neurodegenerative and neurodegenerative differential
diagnoses such as rapidly progressive AD (rpAD). Further,
we investigated plasma Nfl and t-Tau in CJD-subtypes, as-
sociations with other known CJD-biomarkers, influence of
disease stage, and prognostic values. Finally, we compared
the diagnostic and prognostic accuracy of both biomarkers
between plasma and CSF.
Methods
Study design, population, and data acquisition
Data and samples were collected in the framework of a
prospective study on CJD surveillance and diagnostics.
For this retrospective analysis, we utilized the clinical data-
base and the biobank of the German National Reference
Center for Transmissible Spongiform Encephalopathies.
CJD cases were selected on the base of availability of
plasma samples, clinical information, and sufficient diag-
nostic characterization. The clinical and demographic in-
formation had been recorded during the diagnostic
process through a standardized questionnaire including a
third-party anamnesis. Samples from neurological disease
control groups and neurodegenerative dementias were ob-
tained at the Department of Neurology of the University
Medical Center and the National Reference Center for
Creutzfeldt-Jakob disease and healthy controls (HC) at the
Department of Transfusion Medicine, University Medical
Center Göttingen (Germany). A total of 309 plasma sam-
ples were used in this study. Blood was collected in EDTA
tubes and centrifuged at 1500×g and 4 °C for 10min under
same pre-analytical conditions. CSF sampling in CJD cases
was performed at the same day as blood uptake or up to a
maximum of 15 days earlier.
Case and sample characterization
The healthy control (HC) group was composed of
healthy blood donors with absence of any relevant
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clinical findings. The neurological disease control group
was composed of cases diagnosed with neurological con-
ditions either without (NND) or with cognitive impair-
ment or dementia at the time of sampling (NND-Dem).
NDD-Dem cases were initially suspected of CJD (“CJD-
mimics”) but prion diseases were subsequently excluded.
NND and NND-Dem cases were diagnosed according to
acknowledged standard neurologic clinical and para-
clinical findings based on the ICD 10 definitions. The
NND group included the following diagnostic groups:
epilepsy, psychiatric disorders, headache, hypoxia, cere-
bral lymphoma, paraneoplasia, vertigo, vascular enceph-
alopathy, and pain syndromes, while the NND-Dem
group included cerebral vasculitis, normal-pressure
hydrocephalus, Wilson’s disease, CNS neoplasia, enceph-
alitis, ischemic stroke, and dementia due to alcohol
abuse. Alzheimer’s disease (AD) was diagnosed accord-
ing to the National Institute on Aging - Alzheimer’s
Association workgroups (NIA-AA) criteria [4]. Stratifica-
tion of AD cases in slow progressive AD (spAD), and
rapid progressive AD (rpAD) was based on rate of cogni-
tive decline. Rapid progression was defined by a cogni-
tive decline of more than 6 points per year on the Mini
Mental Status Examination (MMSE) scale. Cases with
no rapid progression 1 year before or after blood collec-
tion were classified as rpAD. Velocity of decline was cal-
culated using linear regression (least square method) as
described before [17]. Sporadic Creutzfeldt-Jakob disease
(CJD) cases were diagnosed according to consensus cri-
teria in either probable (clinical diagnosis, n = 15) or def-
inite (neuropathological confirmation, n = 68) [6].
Diagnosis of dementia with Lewy bodies (DLB) was
based on the criteria of McKeith [18]; Parkinson’s dis-
ease dementia (PDD) diagnosis was based on the task
force of the Movement Disorder Society criteria [19] and
differentiated from other Parkinson-plus syndromes
using established diagnostic criteria for corticobasal de-
generation [20], progressive supranuclear palsy [21], and
multiple system atrophy [22]. Fronto-temporal dementia
(FTD) was diagnosed according to the International
Behavioural Variant FTD Criteria Consortium for
bvFTD [23]. Vascular dementia (VaD) diagnosis was
based on clinical and radiological criteria as described by
the (National Institute of Neurological and Communica-
tive Disorders and Stroke and the Alzheimer’s Disease
and Related Disorders Association) [24]. Relevant co-
pathologies were excluded in all diagnostic groups by
clinical criteria and review of the records from the diag-
nostic work-up, including MRI scans. In the VaD group,
CSF p-Tau and beta-amyloid 1-42 were considered to
exclude concomitant AD pathology as far as possible.
To calculate the influence of sampling and disease se-
verity in biomarkers concentrations, CJD cases were
stratified in three categories according to whether blood
was collected in the first, second, or third tertial of the
total disease duration. Additionally, CJD cases were clas-
sified as early stage, in which at least one clinical
hallmark for CJD [6] but no complete loss of communi-
cation ability and voluntary movement was present, and
late stage, akinetic mutism. To evaluate the prognostic
value of plasma Nfl and t-tau as prognostic markers, dis-
ease duration was recorded as the time (in days) from
symptom onset or from blood uptake to the death of the
patient. Symptom onset was evaluated through a third-
party questionnaire (wife, spouse, or 1st grade relative)
and defined as the date either cognitive, visual, balance,
or movement disturbances had become apparent.
Plasma and CSF tests
Plasma Nfl and total tau levels were measured using com-
mercially available kits on the Single molecule array (Simoa)
HD-1 Analyzer (Quanterix). YKL-40 was measured using
the MicroVueYKL-40 EIA ELISA kit from Quidel as previ-
ously described [25]. Total-Prion protein (t-PrP) was quanti-
fied using a fluorometric custom-made ELISA as described
before [26]. CSF Nfl and total-tau (t-tau) were quantified
using the enzyme-linked immunosorbent assay kits NF-light
(UmanDiagnostics) and INNOTEST hTAU-Ag (Fujirebio),
respectively. CSF was analyzed for the presence of 14-3-3
protein using western blot [27]. Amyloid β (Aβ42) was mea-
sured using the INNOTEST® β-AMYLOID ELISA kit from
Fujirebio.
Statistical analysis
Comparison of mean age between diagnostic groups was
performed with ANOVA-test and Tukey correction. Dif-
ferences in the sex ratio were compared with chi-
squared test, and p values were adjusted with the Holm
method. Comparison of biomarker levels among diag-
nostic groups was performed with linear regression
models. Biomarker data were log-transformed, and age
and sex were included as covariates. Multiple compari-
sons of means were performed with Tukey contrasts,
available in the multcomp R package [28]. The same
analysis was applied in the investigation of the influence
of the PRNP codon 129 genotype and the time of sam-
pling on biomarkers levels. Comparison of biomarker
levels in 14-3-3 positive and negative groups was per-
formed using the Mann-Whitney test. Spearman rank
coefficients were used to quantify associations between
continuous biomarkers levels. To assess the diagnostic
accuracy of plasma Nfl and t-tau, receiver operating
characteristic (ROC) curve analyses were carried out and
areas under the curve (AUC) with 95% confidence inter-
vals (95% CI) were calculated. AUC values were com-
pared with pROC R package, using the Bootstrap
method [29]. The best cutoff values were estimated
based on the Youden index. The CJD cases were
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stratified in two groups based on the duration of the dis-
ease: short course (when disease duration from onset
was below mean disease duration = 165 days) or long
course (otherwise). Differences on biomarker levels be-
tween these two groups were assessed with linear regres-
sion models controlling for demographic covariates
where the biomarker data were log transformed. Rela-
tionship between disease duration and each biomarker
was explored with the non-parametric Spearman correl-
ation coefficient and with Cox proportional hazards
(PH) models controlling for significant covariates (age,
sex, and PRNP codon 129 genotype), using the survival
R package [30]. PH assumption was tested with the
Schoenfeld residuals against the transformed time. To
allow for non-linear associations between biomarker
data and disease duration, we employed the multivari-
able fractional polynomial method, using the mfp pack-
age in R [31]. Graphical representation of regression
models was performed with visreg R package [32]. Statis-
tical significance was considered at p < 0.05.
Results
Plasma Nfl and t-tau in controls, CJD, and differential
diagnoses
Data on age, sex, and plasma biomarkers for the study
cohort are presented in Table 1. No significant differ-
ences on age were detected between diagnostic groups.
Statistically significant differences in the sex ratio were
detected in CJD compared to DLB/PDD (p = 0.04) and
to HC (p = 0.0016). In HC, mean values of Nfl differed
between sexes (female = 8.03 pg/mL, male = 9.75 pg/mL)
with borderline significance (p = 0.044) whereas no sig-
nificant differences were detected for Nfl in CJD and for
t-tau in both groups.
The highest Nfl concentrations were detected in CJD
followed by NND-Dem, VaD, DLB/PDD, AD, FTD,
NND, and HC (Table 1 and Fig. 1a). In a multi-
comparative analysis corrected for covariates, Nfl con-
centrations were increased in CJD compared to HC,
NND, AD, DLB/PDD, FTD, and VaD (p < 0.001), in AD
compared to HC (p < 0.001) and NND (p = 0.002), in
DLB/PDD compared to HC and NND (p < 0.001), in
FTD compared to HC (p = 0.020), and in VaD compared
to HC and NND (p < 0.001). Additionally, significantly
higher Nfl concentrations were observed in NND-Dem
compared to HC, NND, AD, DLB/PDD, FTD, and VaD
(p < 0.001) (Fig. 1a, c). In contrast, t-tau was exclusively
increased in CJD, with significantly different concentra-
tions when compared to HC, NND, NND-Dem, AD,
DLB/PDD, FTD, and VaD (p < 0.001) (Fig. 1b, c).
The diagnostic accuracy of Nfl and t-tau discriminat-
ing the different diagnostic groups was calculated using
the areas under the curve (AUC) and 95% confidence in-
tervals (95% CI) (Table 2). Nfl was able to differentiate
HC and NND from neurodegenerative dementias with
good accuracy (AUC > 0.81 in all cases, with the excep-
tion of the NND vs. FTD comparison, AUC = 0.66). Nfl
displayed a remarkable discriminatory value for CJD
compared with non-demented controls (AUC = 1, vs.
HC and AUC = 0.97 vs. NND). High Nfl levels in NND-
Dem were translated in AUC values ranging from 0.88
to 0.97 discriminating AD, DLB/PDD, FTD, and VaD







Plasma Nfl (pg/mL) Plasma t-Tau (pg/mL)
Mean + SD 95% CI Mean + SD 95% CI
Controls
HC 70 22/48 64.7 ± 5.1 – 9.2 ± 3.4 8.4–10.0 2.5 ± 1.2 2.3–2.8
NND 26 13/13 64.1 ± 6.9 – 23.4 ± 39.6 7.4–39.5 3.7 ± 2.4 2.7–4.7
NND-Dem 17 9/8 63.2 ± 16.9 – 182.2 ± 151.5 104.3–260.1 3.1 ± 2.4 1.8–4.3
Neurodegenerative and vascular dementia
AD 44 26/18 68.5 ± 10.9 – 34.9 ± 33.4 24.7–45.8 3.6 ± 2.4 2.8–4.3
CJD 83 53/30 66.6 ± 8.8 273.4 ± 276.9 349.7 ± 505.4 239.4–460.1 45.1 ± 48.7 34.5–55.7
MM 51 36/16 66.8 ± 9.6 236.9 ± 213.7 384.5 ± 492.7 246.0–523.1 59.8 ± 54.4 44.6–75.1
MV 11 4/7 65.6 ± 7.1 316.3 ± 20.1 174.9 ± 118.4 95.3–254.4 23.7 ± 24.9 6.9–40.4
VV 18 11/7 68.9 ± 6.7 369.5 ± 417.3 395.1 ± 689.4 52.3–737.9 16.5 ± 19.3 6.9–26.2
DLB/PDD 35 11/24 69.8 ± 8.3 – 46.8 ± 37.1 33.8–59.7 2.3 ± 1.4 1.8–2.7
FTD 12 8/4 69.5 ± 7.2 – 27.8 ± 29.6 7.9–47.8 2.3 ± 1.3 1.4–3.1
VAD 22 15/5 70.0 ± 9.9 – 56.35 ± 51.7 33.4–79.3 3.2 ± 2.8 2.0–4.8
Number of cases studied, sex (number of female and male cases), age at onset (mean age with SD), and plasma Nfl and t-tau (mean concentrations with SD and
95% CI) are indicated. Information on disease duration (onset to death, mean days, SD) is only available for the CJD group. HC, healthy controls; NND, neurological
diseases without dementia; NND-Dem, neurological diseases with dementia; AD, Alzheimer’s disease; CJD, Creutzfeldt-Jakob disease; MM/MV/VV, PRNP codon 129
methionine/valine polymorphism; DLB/PDD, dementia with Lewy bodies/Parkinson’s disease dementia; FTD, fronto-temporal dementia; VaD, vascular dementia;
Nfl, neurofilament light; t-tau, total-tau. *Information on disease duration was available from 82 of 83 CJD cases
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cases and lower accuracy discriminating from CJD cases
(AUC = 0.67). In contrast, t-tau exclusively displayed a
good discriminatory value in the differentiation of CJD
from HC, NND, and NND-Dem (AUCs values ranging
from 0.91 to 0.95). Significant differences in AUC values
between Nfl and t-tau for each comparison indicates
high specificity for t-tau in the discrimination of CJD
cases from the other diagnostic groups, while Nfl re-
sulted in a less specific test with a good diagnostic value
in the discrimination of all conditions associated to de-
mentia from HC and NND (Fig. 1c, Table 2). Overall,
Nfl presented a slightly superior, but not significant, ac-
curacy compared to t-tau in discriminating CJD from
neurodegenerative dementias, with the exception of the
AD vs. CJD comparison where Nfl significantly over per-
forms t-tau (Table 2).
Plasma Nfl and t-tau displayed a positive and significant
association in the NND-Dem (cc: 0.6957, p = 0.0019) and
CJD (cc: 0.3676, p < 0.001) groups (Additional file 1A and
1B), while no other significant correlations were detected
in the rest of the diagnostic groups (p > 0.05). In CJD, a
significant positive correlation was observed between
plasma and CSF Nfl concentrations (cc: 0.5125, p < 0.001)
(Additional file 1C) and between plasma and CSF t-tau
concentrations (cc: 0.5425, p < 0.001) (Additional file 1C).
Plasma Nfl was associated with CSF t-tau (cc: 0.3266, p =
0.0109), but plasma t-tau was not associated with CSF Nfl.
Plasma t-tau was associated with CSF 14-3-3 positivity
(p = 0.0211). Plasma Nfl and t-tau were associated neither
with CSF Aβ42 nor with CSF t-PrP. Plasma Nfl, but not t-
tau, significantly correlated with plasma YKL-40 (cc:
0.4030 p = 0.0081) (Additional file 1C).
Plasma Nfl and t-tau cutoff points for the differential
diagnosis of CJD
Cutoff points and associated sensitivity and specificity
values for the discrimination of CJD from HC and non-
CJD-Dem (NND-Dem, AD, FTD, DLB/PDD and VaD)
were determined. Due to the significant differences on
Nfl concentrations between AD, FTD, DLB/PDD, VaD
Fig. 1 Plasma Nfl and t-tau in the differential diagnosis of neurodegenerative dementia. Dot plot displaying a Nfl and b t-tau concentrations in
the differential diagnosis of neurodegenerative dementia. c Statistical significance derived from a multi-comparative analysis corrected for
covariates for Nfl and t-tau among the diagnostic groups (linear regression models were used, as explained in the “Statistical analysis” section).
The Tukey-corrected p values for each pair of diagnostic group comparison are indicated. HC, healthy controls; NND, neurological diseases
without dementia; NND-Dem, neurological diseases with dementia; AD, Alzheimer’s disease; CJD, Creutzfeldt-Jakob disease; DLB/PDD, dementia
with Lewy bodies/Parkinson’s disease dementia; FTD, fronto-temporal dementia; VaD, vascular dementia; Nfl, neurofilament light; t-tau, total-tau; f,
female; m, male; SD, standard deviation
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and NND-Dem, an additional group including only neu-
rodegenerative dementias (AD, FTD, DLB/PDD and
VaD) named non-CJD neurodeg-Dem was defined and
included in the analysis. At 33 pg/mL Nfl cutoff, CJD
was discriminated from HC with 100% sensitivity and
specificity. At 70 pg/mL Nfl cutoff, CJD was discrimi-
nated from non-CJD-Dem with 79% sensitivity and 96%
specificity and from non-CJD neurodeg-Dem (excluding
NND-Dem) with 88% sensitivity and 96% specificity
(Table 3). At 6.0 pg/mL t-tau cutoff, CJD was discrimi-
nated from HC with 84% sensitivity and 100% specificity.
At 6.1 pg/mL t-tau cutoff, CJD discriminated from non-
CJD-Dem and non-CJD neurodeg-Dem with 95% sensi-
tivity and 84% (Table 3).
Plasma Nfl and t-tau in the differential diagnosis of CJD
from AD subtypes
Rapid progressive forms of AD have been widely de-
scribed, being one of the main differential diagnosis of
CJD due to their partial overlap on clinical presentation
and biomarker profile [33]. Thus, we examined whether
different Nfl and t-tau profiles were observed between
slow progressive (spAD) and rapid progressive (rpAD)
AD cases. Plasma Nfl displayed significantly higher con-
centrations in rpAD (52.1 ± 49.6 pg/mL) than in spAD
(25.5 ± 11.7 pg/mL) (Fig. 2a), with an associated AUC of
0.79 (95%CI = 0.64–0.93). In contrast, no differences in
t-tau concentrations were observed between rpAD
(3.3 ± 1.7 pg/mL) and spAD (3.3 ± 1.1 pg/mL) (Fig. 2b),
with an associated AUC of 0.57 (95%CI = 0.37–0.77).
The higher Nfl concentrations in rapid progressive
forms of AD were in agreement with a significant nega-
tive correlation between Nfl and MMSE score (Fig. 2c),
an association that was not observed for t-tau (Fig. 2d).
To investigate this further and to exclude that the
plasma Nfl differences between spAD and rpAD are
solely associated with lower MMSE scores in the rpAD
group, we performed an additional linear regression
model. When age, sex, and MMSE scores were included,
higher Nfl concentrations still showed a significant asso-
ciation with rpAD (p = 0.028). Nfl had a higher accuracy
than t-tau discriminating CJD from spAD (Nfl AUC =
0.99 vs. t-tau AUC = 0.95) and CJD from rpAD (Nfl
AUC = 0.95 vs. t-tau AUC = 0.92). However, differences
between AUCs were only significant for the spAD vs.
CJD comparison (Fig. 2e).
Influence of codon 129 PRNP genotype and CJD subtype
To further investigate the role of different CJD subtypes
in plasma Nfl and t-tau concentrations, CJD cases were
stratified according to codon usage (Methionine (M) or
Valine (V)) at position 129 of the PRNP gene. It deter-
mines the clinico-pathological features of the disease
[34] and is a well-known modifier of Nfl and t-tau ac-
curacy in biological fluids in prion diseases [7, 14, 15,
35]. In a multi-comparative analysis corrected for covari-
ates, no significantly different Nfl concentrations were
detected between MM (384.5 ± 492.7 pg/mL), MV
(174.9 ± 118.4 pg/mL), and VV (395.1 ± 689.4 pg/mL)
cases (Fig. 3a). In contrast, t-tau concentrations were sig-
nificantly higher in MM (59.4 ± 54.4 pg/mL) compared
to MV (23.6 ± 24.9 pg/mL) and to VV (16.5 ± 19.3 pg/
mL) cases (Fig. 3b). Given the influence of codon 129
PRNP genotype on Nfl and t-tau profiles in CJD cases,
we sought to determine the diagnostic performance of
Table 2 Diagnostic value of plasma Nfl and t-tau in the
differential diagnosis of neurodegenerative dementias
Nfl t-tau
AUC 95% CI AUC 95% CI p value
HC vs. AD 0.97 0.94–0.99 0.67 0.57–0.77 < 0.001
HC vs. CJD 1 1 0.95 0.91–0.98 0.003
HC vs. DLB/PDD 0.95 0.91–0.99 0.57 0.46–0.70 < 0.001
HC vs. FTD 0.81 0.61–1 0.60 0.42–0.80 0.1
HC vs. VaD 0.99 0.99–1 0.55 0.39–0.67 < 0.001
NND vs. AD 0.82 0.70–0.93 0.52 0.37–0.67 < 0.001
NND vs. CJD 0.97 0.94–1 0.91 0.86–0.96 0.05
NND vs. DLB/PDD 0.84 0.72–0.95 0.71 0.57–0.85 0.1
NND vs. FTD 0.66 0.46–0.87 0.69 0.52–0.87 0.7
NND vs. VaD 0.90 0.80–1 0.62 0.45–0.78 0.002
NND-Dem vs. AD 0.95 0.90–1 0.62 0.44–0.80 < 0.001
NND-Dem vs. CJD 0.67 0.53–0.80 0.93 0.89–0.98 < 0.001
NND-Dem vs. DLB/PDD 0.91 0.83–0.99 0.56 0.42–0.77 0.001
NND-Dem vs. FTD 0.97 0.90–1 0.58 0.36–0.79 < 0.001
NND-Dem vs. VaD 0.88 0.78 0.99 0.51 0.32–0.69 0.002
AD vs. CJD 0.98 0.96–1 0.91 0.87–0.96 0.01
AD vs. DLB/PDD 0.62 0.49–0.75 0.72 0.61–0.84 0.3
AD vs. FTD 0.66 0.46–0.85 0.70 0.51–0.88 0.7
AD vs. VaD 0.69 0.56–0.82 0.63 0.48–0.79 0.6
CJD vs. DLB/PDD 0.96 0.93–0.99 0.96 0.92–0.99 0.7
CJD vs. FTD 0.98 0.95–1 0.96 0.92–0.99 0.2
CJD vs. VaD 0.94 0.88–0.99 0.93 0.88–0.98 0.8
DLB/PDD vs. FTD 0.72 0.54–0.90 0.51 0.30–0.70 0.08
DLB/PDD vs. VaD 0.47 0.37–0.68 0.60 0.45–0.75 0.3
FTD vs. VaD 0.82 0.65–0.99 0.63 0.40–0.82 0.1
AUC derived from ROC curves, with 95% CI in the comparative analysis of HC,
NND, and NND-Dem vs. neurodegenerative dementia and between the
different neurodegenerative dementia groups are indicated. Statistical
differences (p values) between AUC values for Nfl and t-tau in the
comparisons between pairs of diagnostic groups calculated as explained in
the “Statistical analysis” section. AUC, area under the curve; ROC, receiver
operating characteristic; 95% CI, 95% confidence interval; HC, healthy controls;
NND, neurological diseases without dementia; NND-Dem, neurological
diseases with dementia; AD, Alzheimer’s disease; CJD, Creutzfeldt-Jakob
disease; DLB/PDD, dementia with Lewy bodies/Parkinson’s disease dementia;
FTD, fronto-temporal dementia; VaD, vascular dementia; Nfl, neurofilament
light; t-tau, total-tau
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Table 3 Diagnostic accuracy of plasma Nfl and t-tau in the discrimination of CJD
Plasma Nfl Plasma t-tau
CJD vs. Cutoff Sensitivity (%) Specificity (%) Cutoff Sensitivity (%) Specificity (%)
HC > 33 pg/mL 100 100 > 6.0 pg/mL 84 100
Non-CJD-Dem > 70 pg/mL 79 96 > 6.1 pg/mL 95 84
Non-CJD-neurodeg-Dem > 70 pg/mL 88 96 > 6.1 pg/mL 95 84
Sensitivity (in %), specificity (in %), and associated cutoff points (in pg/mL) for plasma Nfl and t-tau in the discrimination of CJD from HC, non-CJD-Dem, and
non-CJD neurodeg-Dem
Fig. 2 Plasma Nfl and t-tau in different AD subtypes and discrimination from CJD. Dot plot displaying a Nfl and b t-tau concentrations in HC (n =
70), NND (n = 26), spAD (n = 24), and rpAD (n = 16). Statistical significance derived from a comparative analysis corrected for covariates is
indicated. Correlation analysis between plasma Nfl (c) and t-tau (d) concentrations with MMSE in AD cases. Correlation coefficients with 95% CI
and associated p values derived from Spearmen test analysis are indicated. e AUC derived from ROC curves, with 95% CI in the comparative
analysis of spAD and rpAD from CJD cases. p values derived from the comparative analysis of AUCs are indicated (corresponding statistical test is
explained in Statistical analysis). AD, Alzheimer’s disease; spAD, slow progressive AD; rpAD, rapid progressive AD; Nfl, neurofilament light; t-tau,
total-tau; AUC, area under the curve; ROC, receiver operating characteristic; 95% CI, 95% confidence interval
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both biomarkers in the discrimination of CJD from
neurodegenerative dementias from a non-prion eti-
ology. To this purpose, different types of dementias
(NND-Dem, AD, DLB/PDD, FTD, and VaD) were
grouped under the non-CJD dementia label (non-
CJD-Dem), and AUC values calculated for CJD cases
stratified by codon 129 genotype. In total CJD cases,
equal AUCs were obtained for Nfl and t-tau in the
discrimination of non-CJD-Dem (AUC = 0.93) (Fig. 3c,
d). Stratification by PRNP codon 129 genotype had a
stronger influence in t-tau (AUCs ranging from 0.86
to 0.96), than in Nfl (AUCs ranging from 0.90 to
0.94).
Regarding CJD subtype, data were available for the
two most prevalent subtypes. While no differences were
detected in Nfl concentrations between MM1/MV1
(423.1 ± 561.9 pg/mL) and VV2 (233.6 ± 122.9 pg/mL)
cases (Fig. 3e), t-tau was significantly increased in MM1/
MV1 (75.0 ± 58.2 pg/mL) compared to VV2 (17.4 ± 21.7
pg/mL) cases (Fig. 3f).
Fig. 3 Influence of codon 129 PRNP genotype and subtype in plasma Nfl and t-tau in CJD. a Nfl and b t-tau concentrations in CJD stratified by
prion protein gene (PRNP) codon 129 genotype (MM, n = 51; MV, n = 11; VV, n = 18). Statistical significance derived from a multi-comparative
analysis corrected for covariates for Nfl and t-tau is indicated (linear regression models were used, as explained in the “Statistical analysis” section).
Dot plots with mean (line) values are shown. ROC curves for Nfl (c) and t-tau (d) in the comparative analysis of non-CJD-Dem vs. CJD cases
stratified by codon 129 PRNP genotype. AUC derived from ROC curves, with 95% CI in the comparative analysis of non-CJD-Dem vs. total CJD
cases and CJD cases stratified by codon 129 PRNP genotype are shown. e Nfl and f t-tau concentrations in CJD MM1/MV1 (n = 23) and VV2 (n =
12) subtypes. Statistical significance derived from a comparative analysis corrected for covariates is indicated. Dot plots with mean (line) values
are shown. Non-CJD-Dem, non-neurodegenerative dementia; Nfl, neurofilament light; t-tau, total-tau
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Relation with disease stage and prognostic value of
plasma Nfl and t-tau in CJD
To evaluate a potential association between Nfl and t-
tau levels at the time of blood collection and the timeli-
ness of the disease in CJD patients, samples were strati-
fied in early (1st Ter), middle (2nd Ter) and late stages
(3rd Ter). However, neither Nfl nor t-tau concentrations
were significantly different between disease stages
(Fig. 4a, b). Next we stratified cases according whether
patients presented early symptoms or akinetic mutism at
the time of sampling (as explained in Study Population).
Cases in akinetic mutism showed significantly higher Nfl
and t-tau levels than those at early stage of the disease
(Fig. 4c, d).
To ascertain whether plasma Nfl and t-tau were asso-
ciated to disease duration, CJD cases were stratified in
those displaying short and long course (lower and higher
than mean disease duration, respectively). Nfl concentra-
tions were not significantly different between CJD cases
displaying short and long survival times. In contrast,
higher t-tau concentrations were detected in CJD cases
with short survival time (p = 0.0088). Association be-
tween disease duration and biomarker data was explored
with Spearman correlation coefficients. Due to the diffi-
culty to precisely define disease duration in prion dis-
eases, in our study, we considered two starting points:
from disease onset to death and from blood uptake to
death. Significant associations were observed in the case
of t-tau (cc = − 0.3236 and cc = − 0.3166, when disease
duration was considered from disease onset and blood
uptake respectively), but not in the case of Nfl (Fig. 4d–
f). Given these results, we built Cox PH models with t-
tau and Nfl as predictors to observe the effect over
disease duration. As expected, only t-tau behaved as a
significant predictor, although with very modest hazard
ratios (HR), which is not surprising considering the unit
used to measure the biomarker (pg/mL) (Add-
itional file 2). Non-linear relationships between disease
duration and plasma t-tau were also explored (Add-
itional file 2), but the best models displayed only moder-
ate fitting, with concordance indices of 0.6 (i.e., 60% of
concordant prediction-value pairs) [36].
Comparative analysis of plasma and CSF accuracy in CJD
diagnosis and prognosis
In order to comparatively evaluate the accuracy of
plasma and CSF Nfl and t-tau, both biomarkers were
measured in available paired CSF cases in CJD and neu-
rodegenerative dementia (non-CJD-Dem) cases. Plasma
and CSF Nfl showed a similar accuracy in discriminating
non-CJD-Dem from CJD (plasma AUC = 0.91 and CSF
AUC = 0.90) (Fig. 5a). In contrast, CSF t-tau (AUC =
0.97) displayed superior accuracy than plasma t-tau
(AUC = 0.93) in the same comparative analysis (Fig. 5b).
Association between biomarkers and disease duration
was explored with Spearman correlation coefficient to
compare the potential prognostic value of CSF vs.
plasma markers in the group of available paired cases.
While both CSF t-tau and Nfl levels were strongly in-
versely associated with disease duration, particularly
when this was measured from blood uptake (cc = −
0.5093 and cc = − 0.3983 for CSF t-tau and CSF Nfl, re-
spectively), only plasma t-tau showed association with
disease duration (cc = − 0.2803). As also observed in the
previous section, plasma Nfl totally lacked of prognostic
value (Fig. 5c).
Discussion
Plasma Nfl and t-tau in the differential diagnosis of CJD
The differential diagnosis of neurodegenerative dementia
may be challenging due to overlapping clinical features
among different conditions. Here, we explored the diag-
nostic accuracy of plasma Nfl and t-tau in the differen-
tial diagnosis of CJD, identified the influence of
demographic and genetic factors on biomarker levels
and determined the diagnostic value of both biomarkers
in the differential diagnostic context. Our data validate
previous reports describing elevated blood Nfl and t-tau
in CJD compared to HC [14, 15] as well as to non-
demented controls [11].
Additionally, we observed that, despite the overall ac-
curacy of both biomarkers discriminating CJD from
non-CJD dementias is similar (AUC = 0.93), t-tau con-
centrations are dependent on the genetic characteristics
of the CJD population (codon 129 genotype). Import-
antly, the accuracy of both biomarkers is highly
dependent to the diagnostic group to which CJD is com-
pared. In this regard, while Nfl displays a high sensitivity
discriminating CJD from non-demented controls, test
specificity is hampered by the presence of high concen-
trations in non-CJD dementias. In contrast, t-tau was
somewhat less sensitive than Nfl discriminating CJD
form non-demented controls, but offers higher test spe-
cificity for CJD. This, together with the observation that
Nfl concentrations are significantly higher in NND-Dem
compared with non-CJD neurodegenerative dementias,
discloses the complementarity of both biomarkers in the
differential diagnosis of CJD. Thus, t-tau performs better
than Nfl in discriminating CJD from NND-Dem,
whereas Nfl becomes more useful in discriminating early
CJD with non-specific symptoms from NND. For the
differentiation of CJD from neurodegenerative demen-
tias, slightly superior but not significantly higher accur-
acies were achieved by Nfl compared to t-tau, with the
exception of the CJD vs. AD comparison for which Nfl
significantly outperforms t-tau. In this regard, we also
explored the value of plasma Nfl and t-tau in rpAD,
which represents a recurrent alternative diagnosis in
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cases referred to prion disease surveillance centers due
to its clinical overlap with CJD [34]. The stratification of
AD according to rate of cognitive decline reveals that, in
spite of the higher Nfl concentrations in rpAD compared
to spAD, Nfl performs better than t-tau discriminating
rpAD from CJD (AUC 0.95 vs. 0.92). Interestingly, ele-
vated Nfl has been reported in other non-CJD rapid pro-
gressive neurological syndromes including AD and those
presenting vascular, neoplastic and inflammatory alter-
ations [14].
We report distinctive optimal cutoff points considering
that the diagnostic accuracy may vary with clinically sus-
pected etiology of differential diagnoses. An optimal cut-
off for t-tau (6.1 pg/mL) displays same accuracy
discriminating CJD from the rest of dementia syndromes
regardless their etiology whereas Nfl sensitivity resulting
from the optimal cutoff of 70 pg/mL decreases when the
NND-Dem group is included, as a consequence of its
above mentioned high Nfl concentrations. However,
these cutoffs cannot be applied in a clinical context until
Fig. 4 Relation with disease stage and prognostic value of plasma Nfl and t-tau in CJD. Plasma Nfl (a) and t-tau (b) concentrations in CJD cases
stratified in three categories according to whether blood was collected in the first stage/tertial (1st Ter, n = 17) (time of blood uptake to disease
onset/total duration of the disease < 0.33), second stage/tertial (2nd Ter, n = 20) (0.33–0.66), or third stage/tertial (3rd Ter, n = 46) (> 0.66) of the
disease. Plasma Nfl (c) and t-tau (d) in CJD cases classified as early stage (n = 51) and akinetic mutism (n = 31). Resultant significant corrected p
values are displayed. Nfl, neurofilament light; t-tau, total-tau. d–f Association between disease duration (considered from disease onset and from
blood uptake) and plasma Nfl and t-tau, measured with Spearman correlation coefficients (cc) and corresponding p values
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they have been validated in independent cohorts. Differ-
ent cutoff points have been described in the bibliog-
raphy, e.g., 2.2 pg/mL for t-Tau and 44.7 pg/mL for NfL
[11], but these were not comparable to the present ones
as they were obtained in serum and included prion dis-
eases from different etiologies and a mixture of non-
demented and demented controls.
In agreement with previous observations, we validated
the role of codon 129 genotype in t-tau concentrations
in CJD [14, 15], with MM cases presenting higher t-tau
concentrations than those harboring MV and VV. Im-
portantly, knowledge about PRNP codon 129 genotype
and the type of suspected differential diagnosis (either a
non-neurodegenerative neurological disease with de-
mentia syndrome or a neurodegenerative dementia) may
be useful in determining which biomarker may display
higher clinical value in the differential diagnosis of CJD.
Similarly, our analyses put forward the possibility to de-
termine distinct cutoff points for each codon 129 geno-
type, which will probably result in improved
classification performance in the case of t-tau. Regarding
autopsy-confirmed confirmed CJD cases, t-tau, but not
Nfl, concentrations were significantly higher in CJD
MM1/MV1 compared to VV2 cases in agreement with
previous data [37], suggesting that despite positive corre-
lations in plasma, Nfl, and t-tau reflect different (or only
partially overlapping) pathological features in brain
tissue. In this regard, while Nfl is mainly expressed in
myelinated subcortical axons [38], t-tau displays a widely
neuronal expression in the brain [39], and different
strain-dependent regional neuronal vulnerability has
been reported in CJD [34, 40]. Additionally, differences
can be attributed to differential entrance and stability of
both proteins in the bloodstream.
Because blood collection is performed at different
stages of the disease, we analyzed the influence of the
time of sampling in the biomarker levels in CJD. Cases
in akinetic mutism at the time of sampling had higher
plasma Nfl and t-tau levels than those at early stages of
the disease. These data are in line with previous studies
demonstrating the relationship between plasma t-tau
and Nfl with disease progression in CJD [41]. In con-
trast, no differences were found between time points
during disease course (tertials), potentially due to het-
erogeneous application of life-extending treatment or
earlier blood uptakes in patients with fast disease
progression.
An important observation of this study is that while
plasma and CSF Nfl display similar accuracies in the dis-
crimination of CJD from non-CJD dementias, CSF t-tau
outperforms plasma t-tau, as well as plasma and CSF Nfl.
This is in agreement with previous reports showing high-
est accuracies for CSF t-tau comparing CJD vs. non-CJD
cases among the four biomarker combinations [11, 37].
Fig. 5 Comparative analysis of plasma and CSF biomarkers accuracy in CJD diagnosis and disease duration. a, b ROC curves with associated AUC
values in the comparative analysis of CJD (n = 51) vs. non-CJD-Dem (n = 118) groups obtained with t-tau and Nfl in CSF and plasma. c Association
of plasma and CSF t-tau and Nfl with disease duration measured with Spearman correlation coefficients (cc) and corresponding p values
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The observation that Nfl and t-tau exclusively correlate in
NND-Dem and CJD groups, both displaying extremely
high Nfl values, may help to shed some light on the differ-
ent clearance pathway of both proteins from plasma. We
hypothesize that when moderate neuronal damage occurs,
different clearance or turnover mechanisms lead to an ab-
sence of correlation between both biomarkers. Instead,
when massive neuronal damage occurs, this effect is
masked by massive accumulation of both proteins in
plasma leading to a positive correlation between both pro-
teins. Whether blood concentrations do really mirror
alterations in the brain tissue needs to be carefully ad-
dressed. Some biomarkers may be expressed in other tis-
sues or their concentrations in blood may not reflect
alterations in brain due to different interchange mechan-
ism between fluids, different modifications and forms. In
this sense, our correlation analyses in paired plasma-CSF
cases indicate that the plasma levels of both proteins re-
flect cerebral alterations.
Plasma Nfl and t-tau in AD and VD
We also validated previous observations in AD, report-
ing moderately increase or no significance differences on
plasma t-tau levels between AD and cognitive normal
controls [42, 43]. However, while plasma t-tau lacks ac-
curacy as a diagnostic AD marker, it is associated with
an increased risk of cognitive decline in MCI [44] and
AD [45] being proposed as a potential non-specific pre-
dictive biomarker of dementia [45]. Interestingly, in our
AD group, plasma Nfl, but not t-tau, showed a signifi-
cant association with MMSE. This is in agreement with
data reporting increasing Nfl concentrations with in-
creasing symptoms severity [46] and its correlation with
CSF AD markers, hippocampal volume loss, and FDG-
PET hypometabolism [47, 48]. Our analyses in VaD
cases showed high levels of plasma Nfl (only lower than
those of CJD and NND-Dem), which is in line with pre-
vious studies demonstrating the association of plasma
Nfl and the risk of VaD [49]. By contrast, plasma t-tau
was not altered in VaD. Indeed, it seems that this bio-
marker in case of vascular disease is only a good marker
in acute cerebrovascular events [50].
Prognostic value of plasma Nfl and t-tau in CJD
Although disease duration in CJD is strongly determined
by individual features such as age at onset, sex and
PRNP codon 129 genotype [51, 52], the potential prog-
nostic capacity of several fluid biomarkers is under in-
vestigation, with t-tau highlighting as one of the more
promising candidates [52, 53]. In the present work, we
observed a strong association between disease duration
and plasma t-tau in CJD, in line with previous reports
[37, 53]. It was shown that the combinatory use of infor-
mation on CSF t-Tau and PRNP codon 129 genotype
has a higher prognostic value than genotype alone [52].
Our PH model included codon 129 genotype as a con-
trolling factor and suggests that plasma t-Tau may have
potential to function in a similar way. By contrast, we
did not find a significant association between survival
and plasma Nfl in our study cohort. This association has
been previously reported but seemed to be dependent
on the CJD subtype and, upon stratification of cases,
plasma Nfl was only associated with survival in a group
of slowly progressive prion diseases [37]. Discrepancies
between our findings and previously published studies
can be related to the lack of CJD stratification, which we
chose not to perform since CJD subtype information is
not known at the time of diagnosis. Another reason is
the different definition of survival in CJD. Whereas other
authors considered relevant survival time until akinetic
mutism stage when life-extending treatments are ap-
plied, we strictly considered survival time until death.
This issue involves ethics considerations and needs to be
clarified to reach a consensus definition of survival in
these prognostic analyses.
Study strengths and limitations
The main limitations of our study are the absence of ser-
ial samples, impeding assessment of longitudinal changes
in biomarker levels, and the absence of an external valid-
ation cohort, which implies bias in the reported diagnos-
tic accuracies. We suggest that future validation studies
should aim to include longitudinal samples but this
might be complicated by short survival time in CJD. To
resolve this problem, the intervals between blood up-
takes have to be carefully thought out. Differences might
be detectable even over short time periods of 2 or
4 weeks. In our study, blood and CSF sampling were
performed in close temporal association. In some cases
however, blood-uptake was performed up to a maximum
of 15 days later than lumbar puncture. In the context of
a rapidly progressive diseases, even this rather short
period of time may possibly lead to an overestimation of
the diagnostic accuracy of plasma markers in compari-
son to CSF markers. Although samples from CJD
patients were initially collected in the framework of a
prospective study, case selection was done retrospect-
ively, based on availability of sufficient information and
biomaterial. Naturally, this comes along with potential
biases such as the possibility that the study cohort might
not exactly reflect the phenotypical spectrum of CJD at
diagnosis in the population. On the other hand, the ma-
jority of CJD subtypes and PRNP Codon 129 Genotypes
were MM/MV1 and MM, respectively, similar to what is
known from previous observations [6].
The strengths of our study include the quantification of
the biomarkers in the most common neurodegenerative
dementias relevant in the CJD differential diagnostic
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context, especially the rapidly progressing forms of AD. In
addition, the availability of clinically well-characterized
samples allowed investigating the influence of the time of
blood collection in the biomarker concentrations, which is
uncommon in this type of studies.
Conclusions
In total, our data validate previous observations and
show that plasma Nfl and t-tau are clinically relevant
biomarkers for the diagnosis of CJD with the potential
to become the first blood-based diagnostic biomarkers
to be implemented in the clinical settings. Our data
shows that CJD subtype and certain diagnoses in the
control group are associated with different diagnostic ac-
curacies of plasma Nfl and t-Tau, underlining the im-
portance of a thorough consideration of differential
diagnoses and suggesting potential benefit from a com-
bined use of both biomarkers. Plasma t-tau may also
contribute to predict disease duration in CJD, with im-
plications in counseling and interpretation of clinical tri-
als, whereas plasma Nfl is associated with disease stage
and progression in AD.
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Statistical analysis. B. When allowing for non-linear relationships (using
the multivariable fractional polynomial method), the best fit considering
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transformation of the biomarker data. The Cox PH model rendered a con-
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